Pacific Capital Wealth Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$570K Sell
475
-1
-0.2% -$1.02K 0.09% 56
2026
Q1
$438K Buy
476
+32
+7% +$32.4K 0.07% 60
2025
Q4
$477K Sell
444
-198
-31% -$189K 0.08% 54
2025
Q3
$490K Buy
642
+55
+9% +$40.9K 0.08% 50
2025
Q2
$454K Hold
587
0.08% 51
2025
Q1
$485K Sell
587
-1
-0.2% -$832 0.08% 53
2024
Q4
$454K Sell
588
-17
-3% -$14.1K 0.08% 51
2024
Q3
$536K Buy
605
+31
+5% +$27.9K 0.09% 50
2024
Q2
$520K Buy
574
+137
+31% +$110K 0.09% 45
2024
Q1
$340K Buy
437
+13
+3% +$9.25K 0.08% 50
2023
Q4
$247K Hold
424
0.06% 55
2023
Q3
$228K Buy
+424
New +$218K 0.06% 62

Other funds holding LLY

Pacific Capital Wealth Advisors's LLY Position: Q2 2026 in Review

Pacific Capital Wealth Advisors reduced its Eli Lilly (LLY) stake by 0.21% in Q2 2026, selling an estimated $1.02K and leaving 475 shares worth $570K. The position accounts for 0.09% of the portfolio, ranked #56.

Pacific Capital Wealth Advisors first reported a position in LLY in Q3 2023 and has held it in 12 quarters since. 961 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Pacific Capital Wealth Advisors held 475 shares of Eli Lilly worth $570K as of Q2 2026.
  • Pacific Capital Wealth Advisors sold 1 Eli Lilly share in Q2 2026, an estimated $1.02K.
  • Eli Lilly made up 0.09% of Pacific Capital Wealth Advisors's portfolio in Q2 2026, its #56 holding.
  • Pacific Capital Wealth Advisors first reported a position in Eli Lilly in Q3 2023 and has held it in 12 quarters since.
  • 961 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Pacific Capital Wealth Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.